Is the Availability of Delayed‐Release Prednisone an Important Clinical Advance?

Conn, Doyt L.

doi:10.1002/acr.22745

Search citation statements

Order By: Relevance

Paper Sections

Select...

Cost Effectiveness1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

2021

Publication Types

Select...

Article6

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the USA, however, the same amount of Rayos ® (30 pills) is sold for over $1,600 (cost per-pill: $50). 55 With IR prednisone being priced 13¢ per tablet, MR prednisone is more than 350-fold as expensive as the conventional product. Annual costs for MR prednisone only would be as much as approximately $20,000 (by comparison: etanercept $14,385/year, infliximab $19,283/year).…”

Section: Cost Effectivenessmentioning

confidence: 99%

Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis

Krasselt¹,

Baerwald²

2016

DDDT

View full text Add to dashboard Cite

The introduction of modified-release (MR) prednisone adds a drug with encouraging potential to the armamentarium of the rheumatologist. In particular, for patients experiencing a reduced quality of life due to prolonged morning stiffness, it is a promising therapeutic approach. Two clinical trials and one open-label observational study investigated the effectiveness of MR prednisone in reducing rheumatoid arthritis-related morning stiffness for both new and current users of corticosteroids. The efficacy and safety of MR prednisone use in rheumatoid arthritis patients are reviewed in this article. This includes pivotal trials as well as pathophysiological considerations and clinical implications.

show abstract

Section: Cost Effectivenessmentioning

confidence: 99%